Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613668 | 0.88 | KMT2A (0.41) | PARP1MEN1KMT2AALDH1A1 | |
| SCHEMBL13613666 | 0.88 | P2RX7 (0.42) | PARP1 | |
| SCHEMBL12581661 | 0.86 | PARP1 (0.50) | PARP1PREPMEN1KMT2AHDAC4 | |
| SCHEMBL13613675 | 0.85 | CHRM5 (0.42) | — | |
| SCHEMBL2025050 | 0.84 | PARP1 (0.48) | PARP1PREPMEN1KMT2AHDAC4 | |
| SCHEMBL12581775 | 0.84 | PARP1 (0.48) | PARP1PREPOPRM1OPRK1OPRL1 | |
| SCHEMBL12441825 | 0.84 | PARP1 (0.51) | PARP1PREPMEN1KMT2AHDAC4 | |
| SCHEMBL13613672 | 0.84 | FNTA (0.42) | ALDH1A1 | |
| SCHEMBL13613678 | 0.82 | GRM2 (0.42) | MEN1KMT2A | |
| SCHEMBL13613663 | 0.82 | GRM2 (0.56) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | PARP1 3945/4885PREP 3224/4885MEN1 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.